The Hong Kong financial market has been on a remarkable journey over the past several years, and a brand new era will begin tomorrow when new rules take effect that will open the door to innovative companies that use non-standard share structures and pre-revenue biotech companies. The changes are reflected in new passages in the Listing Rules, but their significance is so much greater: they culminate in the single most transformative change to the market in a quarter century, dating back to the introduction of the H-share regime back in 1993 - Charles Li, CEO, HKEX (28 April 2018).

Related Professionals: Denise Jong May Ling Wong

medical health tablet

Reed Smith was engaged by the Hong Kong Stock Exchange to advise on the drafting of the new listing rules. Denise Jong, May Wong, David Morrison and Nathan Dentice were the lead partners on this project, leveraging on the experience of a global capital markets team in the US and UK and a 100 member strong life sciences global team. Denise has completed more than 50 successful IPOs in her career and prior to May’s legal career, she was a Research Assistant and Technician in the Department of Medicine and Therapeutics of the Chinese University of Hong Kong and was involved primarily in medical research and clinical drug trials. David and Nathan advised on the regulatory enforcement aspects of the new listing rules.

Denise Jong, Managing Partner - Asia Pacific said: “It is a privilege to play an active role in the Hong Kong Stock Exchange’s drive to list innovative and pre-revenue biotech companies in Hong Kong. Our commitment to playing an active part in capital markets innovation in Hong Kong is unwavering”.